Health economic issues in psoriasis

Expert Review of Dermatology

Volumn 3, Issue 4 SUPPL 1, 2008, Pages

  Augustin, Matthias ^a   Radtke, Marc Alexander ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; ETRETIN; INFLIXIMAB; METHOTREXATE;

CONFERENCE PAPER; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; DRUG COST; GERMANY; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE QUALITY; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIASIS; PUVA; QUALITY OF LIFE; ULTRAVIOLET B RADIATION;

EID: 55349089189     PISSN: 17469872     EISSN: None     Source Type: Journal    
DOI: 10.1586/17469872.3.4s.s19     Document Type: Conference Paper

References (6)

1. Augustin M, Reich C, Schaefer I, Zschocke I, Rustenbach SJ. Development and validation of a new instrument for the assessment of patient-defined benefit in the treatment of acne. JDDG 6, 1-8 (2008).
2. Augustin M, Gajur AI, Reich C, Rustenbach SJ, Schaefer I. Benefit evaluation in vitiligo treatment: development and validation of a patient-defined outcomes questionnaire. Dermatology 217, 101-106 (2008).
3. Hankin CS, Feldman SR, Szczotka A et al. A cost comparison of treatments of moderate to severe psoriasis. Drug Benefit Trends 17(5), 200-214 (2005).
4. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 216(4), 366-372 (2007)
5. Kobelt G. Health economic issues in rheumatoid arthritis. Scand. J. Rheumatol. 35(6), 415-425 (2006).
6. Sohn S, Schoeffski O, Prinz J et al. Cost of moderate to servere plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 121(2), 137-144 (2006).